Ugur Sahin Sells 34,000 Shares of BioNTech (NASDAQ:BNTX) Stock

Key Points

• BioNTech CEO Ugur Sahin sold 34,000 shares at an average price of $98.60, generating $3.35 million. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving him with 519,209 shares.
• Sahin has made multiple additional sales in September, selling more than 300,000 shares in total over the disclosed transactions.
• BioNTech shares traded near $96.06, while the company reported a quarterly loss, revenue well below expectations, and a 59.5% year-over-year revenue decline. Analysts nevertheless maintained a consensus “Moderate Buy” rating with a $126 target price.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 34,000 shares of the stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $98.60, for a total transaction of $3,352,400.00. Following the sale, the chief executive officer directly owned 519,209 shares in the company, valued at approximately $51,194,007.40. The trade was a 6.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total value of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total value of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total value of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total transaction of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total transaction of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Price Performance

BioNTech stock traded down $2.60 during midday trading on Friday, reaching $96.06. The company had a trading volume of 1,150,292 shares, compared to its average volume of 1,102,362. The company has a market capitalization of $24.29 billion, a P/E ratio of -12.27 and a beta of 1.29. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The firm's fifty day simple moving average is $97.29 and its 200-day simple moving average is $94.92. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to analysts' expectations of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.BioNTech's quarterly revenue was down 59.5% on a year-over-year basis. During the same quarter last year, the firm posted ($1.60) earnings per share. As a group, equities analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Monaco Asset Management SAM purchased a new stake in shares of BioNTech during the 4th quarter valued at approximately $1,594,000. Hsbc Holdings PLC purchased a new position in BioNTech in the fourth quarter worth approximately $4,969,000. Bank of America Corp DE grew its position in BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock worth $80,261,000 after acquiring an additional 166,432 shares during the period. BNP Paribas Financial Markets increased its stake in BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company's stock worth $150,235,000 after acquiring an additional 474,796 shares during the last quarter. Finally, Amundi increased its stake in BioNTech by 24.5% during the first quarter. Amundi now owns 129,513 shares of the company's stock worth $11,511,000 after acquiring an additional 25,506 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BNTX. Jefferies Financial Group reaffirmed a "buy" rating on shares of BioNTech in a report on Monday, June 1st. Wall Street Zen lowered shares of BioNTech from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Citigroup dropped their price objective on shares of BioNTech from $130.00 to $125.00 and set a "buy" rating for the company in a research note on Wednesday, August 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of BioNTech in a report on Monday, July 6th. Finally, Berenberg Bank set a $140.00 target price on shares of BioNTech in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, BioNTech has an average rating of "Moderate Buy" and a consensus target price of $126.00.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.